Corrigendum to: The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer (Journal of Oncology (2012) 958596) DOI: 10.1155/2012/958596);The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer

Journal of Oncology

Volumn 2017, Issue , 2012, Pages

  Al Shamsi, Humaid O ^a   Lau, Arthur N ^b   Malik, Kartika ^c   Alamri, Abdulaziz ^b   Ioannidis, George ^a   Corbett, Tom ^a   Adachi, J D ^a   Papaioannou, Alexandra ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; GONADORELIN AGONIST; VITAMIN D;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY CANCER; FOLLOW UP; GONADOTROPIN RELEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOPOROSIS; PATIENT CARE; PRESCRIPTION; PROPHYLAXIS; PROSTATE CANCER; SCREENING; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 84861071907     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2017/3432604     Document Type: Erratum

References (45)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010 CA Cancer Journal for Clinicians 2010 60 5 277 300
2. Bolla M., De Reijke T. M., Van Tienhoven G., Van Den Bergh A. C. M., Oddens J., Poortmans P. M. P., Gez E., Kil P., Akdas A., Soete G., Kariakine O., Van Der Steen-Banasik E. M., Musat E., Piérart M., Mauer M. E., Collette L., Duration of androgen suppression in the treatment of prostate cancer New England Journal of Medicine 2009 360 24 2516 2527
3. Satariano W. A., Ragland K. E., (Pubitemid 28419072)
4. Wilt T. J., MacDonald R., Rutks I., Shamliyan T. A., Taylor B. C., Kane R. L., Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer Annals of Internal Medicine 2008 148 6 435 448 (Pubitemid 351665443)
5. Sharifi N., Gulley J. L., Dahut W. L., Androgen deprivation therapy for prostate cancer Journal of the American Medical Association 2005 294 2 238 244 (Pubitemid 41043794)
6. Grossmann M., Hamilton E. J., Gilfillan C., Bolton D., Joon D. L., Zajac J. D., Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy Medical Journal of Australia 2011 194 6 301 306
7. Shahani S., Braga-Basaria M., Basaria S., Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis Journal of Clinical Endocrinology and Metabolism 2008 93 6 2042 2049 (Pubitemid 351831513)
8. Meng M. V., Grossfeld G. D., Sadetsky N., Mehta S. S., Lubeck D. P., Carroll P. R., Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer Urology 2002 60 3, supplement 1 7 12 (Pubitemid 35304536)
9. Damber J. E., Aus G., Prostate cancer The Lancet 2008 371 9625 1710 1721 (Pubitemid 351671887)
10. Lu-Yao G., Stukel T. A., Yao S. L., Changing patterns in competing causes of death in men with prostate cancer: a population based study Journal of Urology 2004 171 6 2285 2290 (Pubitemid 38625453)
11. Alibhai S. M. H., Duong-Hua M., Cheung A. M., Sutradhar R., Warde P., Fleshner N. E., Paszat L., Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men Journal of Urology 2010 184 3 918 923
12. Greenspan S. L., Coates P., Sereika S. M., Nelson J. B., Trump D. L., Resnick N. M., Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer Journal of Clinical Endocrinology and Metabolism 2005 90 12 6410 6417 (Pubitemid 41759293)
13. Alibhai S. M. H., Gogov S., Allibhai Z., Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review Critical Reviews in Oncology/Hematology 2006 60 3 201 215 (Pubitemid 44709617)
14. Smith M. R., McGovern F. J., Zietman A. L., Fallon M. A., Hayden D. L., Schoenfeld D. A., Kantoff P. W., Finkelstein J. S., Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer New England Journal of Medicine 2001 345 13 948 955
15. Smith M. R., Eastham J., Gleason D. M., Shasha D., Tchekmedyian S., Zinner N., Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer Journal of Urology 2003 169 6 2008 2012 (Pubitemid 36576705)
16. Morote J., Morin J. P., Orsola A., Abascal J. M., Salvador C., Trilla E., Raventos C. X., Cecchini L., Encabo G., Reventos J., Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer Urology 2007 69 3 500 504 (Pubitemid 46428384)
17. Shahinian V. B., Kuo Y. F., Freeman J. L., Goodwin J. S., Risk of fracture after androgen deprivation for prostate cancer New England Journal of Medicine 2005 352 2 154 164 (Pubitemid 40096612)
18. Smith M. R., Boyce S. P., Moyneur E., Duh M. S., Raut M. K., Brandman J., Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer Journal of Urology 2006 175 1 136 139 (Pubitemid 41797111)
19. Diamond T. H., Higano C. S., Smith M. R., Guise T. A., Singer F. R., Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies Cancer 2004 100 5 892 899 (Pubitemid 38222847)
20. Duncan G. G., Corbett T., Lukka H., Warde P., Pickles T., GU radiation oncologists consensus on bone loss from androgen deprivation The Canadian Journal of Urology 2006 13 1 2962 2966
21. Papaioannou A., Morin S., Cheung A. M., Atkinson S., Brown J. P., Feldman S., Hanley D. A., Hodsman A., Jamal S. A., Kaiser S. M., Kvern B., Siminoski K., Leslie W. D., 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary Canadian Medical Association Journal 2010 182 17 1864 1873
22. Klotz L., Saad F., PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice Canadian Urological Association Journal 2007 1 1 17 21
23. Ryan C. W., Huo D., Stallings J. W., Davis R. L., Beer T. M., McWhorter L. T., Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy Urology 2007 70 1 122 126 (Pubitemid 47081101)
24. Newton R. U., Galvao D. A., Exercise in prevention and management of cancer Current Treatment Options in Oncology 2008 9 2-3 135 146
25. Planas J., Morote J., Orsola A., Salvador C., Trilla E., Cecchini L., Ravents C. X., Morin J. P., The relationship between daily calcium intake and bone mineral density in men with prostate cancer BJU International 2007 99 4 812 816
26. FDA approval for denosumab,. 2011, http://www.cancer.gov/cancertopics/ druginfo/fda-denosumab
27. Smith M. R., Egerdie B., Toriz N. H., Feldman R., Tammela T. L. J., Saad F., Heracek J., Szwedowski M., Ke C., Kupic A., Leder B. Z., Gossl C., Denosumab in men receiving androgen-deprivation therapy for prostate cancer New England Journal of Medicine 2009 361 8 745 755
28. Alibhai S. M. H., Rahman S., Warde P. R., Jewett M. A. S., Jaffer T., Cheung A. M., Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists Urology 2006 68 1 126 131 (Pubitemid 44037726)
29. Tanvetyanon T., Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy Cancer 2005 103 2 237 241 (Pubitemid 40129281)
30. Wilcox A., Carnes M. L., Moon T. D., Tobias R., Baade H., Stamos E., Elliott M. E., Androgen deprivation in veterans with prostate cancer: implications for skeletal health Annals of Pharmacotherapy 2006 40 12 2107 2114 (Pubitemid 44954427)
31. Yee E. F. T., White R. E., Murata G. H., Handanos C., Hoffman R. M., Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy Journal of General Internal Medicine 2007 22 9 1305 1310 (Pubitemid 47247311)
32. Ebeling P. R., Osteoporosis in men New England Journal of Medicine 2008 358 14 1474 1482
33. Kanis J. A., Oden A., Johansson H., Borgstrm F., Strm O., McCloskey E., FRAX and its applications to clinical practice Bone 2009 44 5 734 743
34. Smith M. R., Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma Cancer 2003 97 supplement 3 789 795 (Pubitemid 36125814)
35. Bae D. C., Stein B. S., The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate Journal of Urology 2004 172 6 2137 2144 (Pubitemid 39507479)
36. Higano C. S., Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician Urologic Clinics of North America 2004 31 2 331 352 (Pubitemid 38581227)
37. Diamond T. H., Winters J., Smith A., De Souza P., Kersley J. H., Lynch W. J., Bryant C., The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study Cancer 2001 92 6 1444 1450 (Pubitemid 32947828)
38. Greenspan S. L., Nelson J. B., Trump D. L., Resnick N. M., Miller M., Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial Annals of Internal Medicine 2007 146 6 416 424 (Pubitemid 351650576)
39. Smith M. R., Egerdie B., Toriz N. H., Feldman R., Tammela T. L. J., Saad F., Heracek J., Szwedowski M., Ke C., Kupic A., Leder B. Z., Gossl C., Denosumab in men receiving androgen-deprivation therapy for prostate cancer New England Journal of Medicine 2009 361 8 745 755
40. Smith M. R., Fallon M. A., Lee H., Finkelstein J. S., Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial Journal of Clinical Endocrinology and Metabolism 2004 89 8 3841 3846 (Pubitemid 39071482)
41. Holick M. F., Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis American Journal of Clinical Nutrition 2004 79 3 362 371 (Pubitemid 41115577)
42. Neubecker K., Adams-Huet B., Farukhi I.M., Delapena R.C., Gruntmanis U., Predictors of fracture risk and bone mineral density in men with prostate cancer on androgen deprivation therapy Journal of Osteoporosis 2011 2011 6
43. Fraser L.-A., Langsetmo L., Berger C., Ioannidis G., Goltzman D., Adachi J. D., Papaioannou A., Josse R., Kovacs C. S., Olszynski W. P., Towheed T., Hanley D. A., Kaiser S. M., Prior J., Jamal S., Kreiger N., Brown J. P., Johansson H., Oden A., McCloskey E., Kanis J. A., Leslie W. D., Fracture prediction and calibration of a Canadian FRAX tool: a population-based report from CaMos Osteoporosis International 2011 22 3 829 837
44. Kanis J. A., McCloskey E. V., Johansson H., Oden A., Strm O., Borgstrm F., Development and use of FRAX in osteoporosis Osteoporosis International 2010 21, supplement 2 S407 S413
45. Ioannidis G., Thabane L., Gafni A., Hodsman A., Kvern B., Johnstone D., Plumley N., Salach L., Jiwa F., Adachi J. D., Papaioannou A., Optimizing care in osteoporosis: the Canadian quality circle project BMC Musculoskeletal Disorders 2008 9, article 130